Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells

Oncotarget

Volumn 6, Issue 17, 2015, Pages 14777-14795

  De Luca, Arianna ^a,b,c   Fiorillo, Marco ^a,b,c   Peiris Pagès, Maria ^a,b   Ozsvari, Bela ^a,b   Smith, Duncan L ^d   Sanchez Alvarez, Rosa ^a,b   Martinez Outschoorn, Ubaldo E ^e   Cappello, Anna Rita ^c   Pezzi, Vincenzo ^c   Lisanti, Michael P ^a,b   Sotgia, Federica ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CALABRIA   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Doxycycline; Drug repurposing; ERR ; PGC1 ; XCT790

Indexed keywords

ACETYLCARNITINE; DOXYCYCLINE; ERRALPHA ESTROGEN-RELATED RECEPTOR; ESTROGEN RECEPTOR; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; NITRILE; OLIGOMYCIN; THIAZOLE DERIVATIVE; XCT790;

BREAST TUMOR; CANCER STEM CELL; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GLYCOLYSIS; HUMAN; LIQUID CHROMATOGRAPHY; MCF-7 CELL LINE; METABOLISM; MITOCHONDRION; MULTICELLULAR SPHEROID; ORGANELLE BIOGENESIS; OXIDATIVE PHOSPHORYLATION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; WNT SIGNALING PATHWAY;

ACETYLCARNITINE; BREAST NEOPLASMS; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, LIQUID; DOXYCYCLINE; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTORS; GLYCOLYSIS; HUMANS; MCF-7 CELLS; MITOCHONDRIA; NEOPLASTIC STEM CELLS; NITRILES; OLIGOMYCINS; ORGANELLE BIOGENESIS; OXIDATIVE PHOSPHORYLATION; PROTEOMICS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TANDEM MASS SPECTROMETRY; THIAZOLES; WNT SIGNALING PATHWAY;

EID: 84934325574     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4401     Document Type: Article

References (47)

1. Sinha N, Mukhopadhyay S, Das DN, Panda PK and Bhutia SK. Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral oncology. 2013; 49:854-862.
2. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M and Stassi G. Therapeutic implications of Cancer Initiating Cells. Expert opinion on biological therapy. 2009; 9:1005-1016.
3. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu Y and Tan W. Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties. Journal of pharmacological sciences. 2013; 122:299-304.
4. Easwaran H, Tsai HC and Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Molecular cell. 2014; 54:716-727.
5. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX and Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nature reviews Clinical oncology. 2015.
6. Angeloni V, Tiberio P, Appierto V and Daidone MG. Implications of stemness-related signaling pathways in breast cancer response to therapy. Seminars in cancer biology. 2015; 31:43-51.
7. Maccalli C and De Maria R. Cancer stem cells: perspectives for therapeutic targeting. Cancer immunology, immunotherapy: CII. 2015; 64:91-97.
8. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G and Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. Journal of mammary gland biology and neoplasia. 2012; 17:111-117.
9. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D and Mor G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Molecular cancer therapeutics. 2011; 10:1385-1393.
10. Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G, Rasola A, Frasson C, Nardo G, Zulato E, Nicoletto MO, Manicone M, Indraccolo S and Amadori A. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014; 5:4305-4319.
11. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP and Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014; 5:11029-11037.
12. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 6:4569-4584.
13. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS and Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:16062-16067.
14. Vlashi E, Lagadec C, Vergnes L, Reue K, Frohnen P, Chan M, Alhiyari Y, Dratver MB and Pajonk F. Metabolic differences in breast cancer stem cells and differentiated progeny. Breast cancer research and treatment. 2014; 146:525-534.
15. Busch BB, Stevens WC, Jr., Martin R, Ordentlich P, Zhou S, Sapp DW, Horlick RA and Mohan R. Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. Journal of medicinal chemistry. 2004; 47:5593-5596.
16. Deblois G and Giguere V. Functional and physiological genomics of estrogen-related receptors (ERRs) in health and disease. Biochimica et biophysica acta. 2011; 1812:1032-1040.
17. Deblois G, St-Pierre J and Giguere V. The PGC-1/ERR signaling axis in cancer. Oncogene. 2013; 32:3483-3490.
18. Fisher KW, Das B, Kortum RL, Chaika OV and Lewis RE. Kinase suppressor of ras 1 (KSR1) regulates PGC1alpha and estrogen-related receptor alpha to promote oncogenic Ras-dependent anchorage-independent growth. Molecular and cellular biology. 2011; 31:2453-2461.
19. Wu F, Wang J, Wang Y, Kwok TT, Kong SK and Wong C. Estrogen-related receptor alpha (ERRalpha) inverse agonist XCT-790 induces cell death in chemotherapeutic resistant cancer cells. Chemico-biological interactions. 2009; 181:236-242.
20. Cassano P, Sciancalepore AG, Pesce V, Fluck M, Hoppeler H, Calvani M, Mosconi L, Cantatore P and Gadaleta MN. Acetyl-L-carnitine feeding to unloaded rats triggers in soleus muscle the coordinated expression of genes involved in mitochondrial biogenesis. Biochimica et biophysica acta. 2006; 1757:1421-1428.
21. Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H and Teh MT. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer research. 2010; 70:9515-9526.
22. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, Sawaya R, Xie K, Yung WK, Medema RH, He X and Huang S. FoxM1 promotes beta-catenin nuclear localization and controls Wnt targetgene expression and glioma tumorigenesis. Cancer cell. 2011; 20:427-442.
23. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, Li Y, Azmi AS, Miele L and Sarkar FH. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Journal of cellular biochemistry. 2011; 112:2296-2306.
24. Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF and Chou CY. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget. 2015; 6:2349-2365.
25. Peiris-Pages M, Sotgia F and Lisanti MP. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine hedgehog-GLI signaling in breast cancer cells. Oncotarget. 6:10728-10745.
26. Bergamaschi A, Christensen BL and Katzenellenbogen BS. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3zeta, FOXM1, and a gene signature associated with mitosis. Breast cancer research: BCR. 2011; 13:R70.
27. Lamb R, Harrison H, Smith DL, Townsend PA, Jackson T, Ozsvari B, Martinez-Outschoorn UE, Pestell RG, Howell A, Lisanti MP and Sotgia F. Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. Oncotarget. 2015; 6:4585-4601.
28. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL and Weinberg RA. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011; 145:926-940.
29. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
30. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Harlow S, Weaver D, Muss H and Plaut K. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast cancer research and treatment. 2009; 114:47-62.
31. Bowling BD, Doudican N, Manga P and Orlow SJ. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer chemotherapy and pharmacology. 2008; 63:37-43.
32. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F and Lisanti MP. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer biology & therapy. 2011; 12:924-938.
33. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F and Lisanti MP. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell cycle. 2011; 10:1271-1286.
34. Lu CL, Qin L, Liu HC, Candas D, Fan M and Li JJ. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition-a Warburg-reversing effect. PloS one. 2015; 10:e0121046.
35. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Pavlides S, Tsirigos A, Ertel A, Pestell RG, Broda P, Minetti C, Lisanti MP and Sotgia F. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell cycle. 2011; 10:4047-4064.
36. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, Lisanti MP and Martinez-Outschoorn UE. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer biology & therapy. 2011; 12:1085-1097.
37. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514:628-632.
38. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, Asara JM and Kalluri R. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nature cell biology. 2014; 16:992-1003, 1001-1015.
39. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell cycle. 2010; 9:3506-3514.
40. Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Power surge: supporting cells "fuel" cancer cell mitochondria. Cell metabolism. 2012; 15:4-5.
41. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013; 496:101-105.
42. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, Bajzikova M, Kovarova J, Peterka M, Yan B, Pesdar EA, Sobol M, Filimonenko A, Stuart S, Vondrusova M, Kluckova K, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell metabolism. 2015; 21:81-94.
43. Salem AF, Whitaker-Menezes D, Howell A, Sotgia F and Lisanti MP. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell cycle. 2012; 11:4174-4180.
44. Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Caveolae and signalling in cancer. Nature reviews Cancer. 2015; 15:225-237.
45. Ertel A, Tsirigos A, Whitaker-Menezes D, Birbe RC, Pavlides S, Martinez-Outschoorn UE, Pestell RG, Howell A, Sotgia F and Lisanti MP. Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle. 2012; 11:253-63.
46. Katajisto P, Dohla J, Chaffer CL, Pentinmikko N, Marjanovic N, Iqbal S, Zoncu R, Chen W, Weinberg RA and Sabatini DM. Stem cells. Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness. Science. 2015; 348:340-343.
47. Holland M, Castro FV, Alexander S, Smith D, Liu J, Walker M, Bitton D, Mulryan K, Ashton G, Blaylock M, Bagley S, Connolly Y, Bridgeman J, Miller C, Krishnan S, Dempsey C, et al. RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood. 2011; 118:638-649.